iBio Inc (IBIO) reported QQ1 2025 with no reported revenue in the period and a continued operating loss framework. The quarter shows an operating loss of $4.106 million and a net loss of $3.989 million, translating to an earnings per share of −$0.46 on 8.633 million weighted average shares. While revenue recognition is not disclosed in the quarter, the expense structure highlights a sustained investment in R&D and general and administrative activities, underscored by a modest depreciation and amortization of $0.278 million and interest expense of $0.057 million. The company generated negative operating cash flow of $3.715 million and consumed $3.164 million of cash during the quarter, ending with roughly $11.04 million in cash and cash equivalents. Net debt stands at about $(6.81) million, reflecting a net cash position despite ongoing losses.
From a balance sheet perspective, iBio remains liquid with a current ratio of 3.37 and total current assets of approximately $11.75 million against current liabilities of roughly $3.47 million. Total assets approximate $24.52 million, while total liabilities run around $6.76 million and stockholders’ equity sits near $17.75 million. The company continues to carry significant accumulated losses (retained earnings around −$317.84 million), consistent with a company in early-stage development and collaboration-driven monetization mode. Strategic momentum centers on iBio’s two-segment model (Biopharmaceuticals and Bioprocessing), ongoing collaborations (e.g., Planet Biotechnology; Texas A&M University System; University of Natural Resources and Life Sciences Vienna; CCPharming), and a portfolio of preclinical and development-stage programs (IBIO100, IBIO200/IBIO201, IBIO400).
On the outlook, management guidance for near-term revenue was not disclosed in the data provided, which underscores the need for new partnerships or milestone-driven collaborations to transition toward profitability. Investors should monitor progress on in-house and partner-driven programs, potential contract development and manufacturing revenue, and any new licensing or collaboration announcements that could meaningfully impact the revenue trajectory and cash runway.